Monika Kmeťová Sivoňová, Peter Kaplán, Zuzana Tatarková, Jana Jurečeková, Henrieta Drobková, Róbert Dušenka, Mark Híveš, Ján Kliment sr.
Introduction and aims: Oncoproteomics allows to identify thousands of proteins that derive from cancer cells, and some of these proteins may be possibly used as therapeutic targets and markers for the early detection, therapy, and prognostic evaluation of cancer patients. Our study aimed to identify potential new prognostic biomarkers and assessment of their performance on aggressiveness and progression of prostate cancer.
Material and methods: Mass spectrometry was used for proteomic profiling of twenty prostate tumours (Gleason score 5-9) and ten BPH tissues as control.
Results: Statistical analysis of the normalized quantities of matched spots revealed that in the prostate cancer group, expression of 82 proteins was more than 1.5-fold changed vs BPH (p<0.05). Among them, we identified mainly cytoskeleton proteins and cytoskeleton-associated proteins such as actin, tropomyosin, desmin, vimentin, transgelin and filamin A.
Conclusions: We assume that proteins identified by this approach may provide actionable guidance for prostate cancer risk assessment and are expected to lead to an era of personalized medicine.